CD27 Monoclonal Antibody (O323), Brilliant Violet™ 605, eBioscience™, Invitrogen™

Description

• CD27 is a 50 kDa member of the tumor necrosis factor (TNF) receptor superfamily that includes CD40 and CD30
• The TNF superfamily members are known for the regulation of cell proliferation and death
• In contrast to the expression of other TNFR/TNF family members, expression of CD27 and its ligand CD70 is predominantly confined to lymphocytes
• High expression levels of CD27 appear to be dependent on proper ligation of antigen receptors
• CD70 expression requires additional co-stimulatory and/or pro-inflammatory signals
• CD27 is expressed as a disulfide-linked homodimer on mature thymocytes, peripheral blood T cells and a subpopulation of B cells
• Activation of T cells via TCR-CD3 complex results in upregulation of CD27 expression on the plasma membrane as well as in the release of its soluble 28-32 kDa form, sCD27, detected in the plasma, urine or spinal fluid
• Soluble CD27 is an important prognostic marker of acute and chronic B cell malignancies
• RgpA, a cystein proteinase, although activating T cells through the protease-activated receptors (PARs), degradates CD27 and counteracts T cell activation mediated by CD27 and its ligand CD70
• CD27-binding protein (SIVA), a proapoptotic protein, can bind to this receptor and is thought to play an important role in the apoptosis induced by this receptor
• Diseases associated with CD27 dysfunction include Lymphoproliferative Syndrome 2 and Autosomal Recessive Lymphoproliferative Syndrome.